Drugs in MeSH Category Antineoplastic Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biocon Pharma	EVEROLIMUS	everolimus	TABLET, FOR SUSPENSION;ORAL	217216-001	Jan 9, 2026	AB	RX	No	No
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-006	Oct 28, 2010	AB	RX	Yes	No	7,491,725*PED				Y
Eugia Pharma	DASATINIB	dasatinib	TABLET;ORAL	216547-002	Apr 22, 2025	AB	RX	No	No

Market Dynamics and Patent Landscape for Antineoplastic Agents (NLM MeSH)

Last updated: April 25, 2026

What drives demand in Antineoplastic Agents markets?

Antineoplastic agents are shaped by a mix of clinical innovation, oncology treatment guidelines, payer constraints, and supply-chain execution. Demand is concentrated in a few high-cost categories: targeted therapies, immune-oncology regimens, and cell and gene therapies moving from niche adoption to broader guideline inclusion.

Demand pillars by drug class

• Immune-oncology and combination regimens: Uptake is driven by line-of-therapy expansion, tumor-agnostic approvals, and companion diagnostics.
• Targeted therapies: Adoption follows biomarker prevalence and resistance-management strategy.
• Cytotoxics and older regimens: Growth is limited by generics but remains stable due to broad usage in combination protocols and cost-sensitive settings.
• Cell and gene therapies: Demand depends on center capacity, reimbursement pathways, and label scope expansion.

Pricing and access pressures that shape launch economics

• Net price compression from biosimilar entry (for biologics) and increased competition within the same MOA family.
• Reimbursement gatekeeping based on biomarker restriction, prior-therapy requirements, and cost-effectiveness thresholds.
• Real-world durability evidence: Payers scrutinize progression-free and overall survival claims against post-market performance.

Competitive consequences for R&D portfolios

• High patent value accrues when companies build stacked protection around:
  • novel targets and MOAs
  • biomarker-defined patient selection
  • dosing regimens (including schedules and maintenance strategies)
  • new combination regimens with differentiated benefit

How does the patent landscape typically look in Antineoplastic Agents?

Oncology patents usually cluster around a few protection layers. In practice, the “real” commercial exclusivity often extends beyond the first composition claims through follow-on filings.

Typical protection stacks in oncology

• Composition of matter: primary drug substance claims (often the earliest priority).
• Formulations: salt forms, polymorphs, solid-state forms, lyophilized forms, and delivery systems.
• Method of treatment: disease indication claims, line-of-therapy language, and biomarker-defined patient subsets.
• Combination therapy: claims that cover a drug in combination with a specific partner agent.
• Manufacturing/process: improvements to synthesis, purification, or scale-up methods.

Filing patterns that influence enforceable exclusivity

• Early target biology filings (broad) followed by later clinical and regimen filings (narrow but enforceable).
• Global filing synchronization: multiple jurisdictions with timed continuations to align claim sets with regulatory review cycles.
• Life-cycle management: serial improvements that preserve market exclusivity even as the earliest claims narrow.

Patent expiry risk points

• Claim narrowing on prosecution can reduce enforceable scope later.
• Orphan and accelerated pathways can lead to fast market entry, compressing the time to build follow-on protection.
• Biosimilar and generic pathways create structural pressure on brand value once foundational claims expire.

Which exclusivity mechanisms matter beyond patents?

Patent exclusivity is only one part of the exclusivity envelope. Market access for antineoplastics also depends on regulatory exclusivity and marketing authorization mechanics.

Key U.S. and E.U. exclusivity mechanisms

• U.S. Hatch-Waxman: Orange Book listing and patents tied to approved drug products can block generic or biosimilar entry where claims are listed and enforceable.
• Biosimilar pathway: reference product exclusivity and interchangeability rules govern timing for biosimilar competition.
• E.U. supplementary protection certificates (SPCs): extend effective patent life for certain medicinal products.

Where does MeSH Class “Antineoplastic Agents” create classification effects?

MeSH is a subject taxonomy, not a legal definition. It aggregates drug concepts under “Antineoplastic Agents,” which can blur apples-to-apples comparisons when translating into patent and commercial landscapes. The MeSH class typically spans:

• cytotoxic chemotherapy agents
• targeted small molecules
• monoclonal antibodies and other biologics
• immune modulators used in cancer treatment
• combination regimens that include antineoplastic agents

Implication for portfolio analytics

Patent activity and market metrics at the MeSH class level must be decomposed by:

• modality (small molecule vs antibody vs nucleic acid vs cell therapy)
• MOA and target class
• therapeutic area (solid tumors vs hematologic malignancies)
• biomarker or companion diagnostic dependency

What are the dominant market dynamics by modality and how do they change patent value?

Small molecules (targeted and kinase inhibitors)

• Patent leverage comes from incremental improvements tied to resistance mutations, dosing schedules, and new biomarker inclusion.
• Generic risk increases earlier because small molecules are easier to replicate once claims narrow or expire.
• Strategic use of follow-on: alternative salts, polymorphs, and method-of-treatment claims.

Monoclonal antibodies (and other biologics)

• Biosimilar threat shapes the patent endgame.
• Patent leverage depends on manufacturing process claims, formulation protection, and combination regimens.
• Efficacy and dosing: biosimilar adoption hinges on clinical equivalence and label scope.

Immunotherapies (checkpoints, co-stimulators, bispecifics)

• High patent density around combinations and biomarker-defined populations.
• Value is sensitive to label expansion and durable response narratives.
• Litigation risk: combinations and new indications are frequent litigation targets.

Cell and gene therapies

• Patent landscape complexity is higher due to:
  • platform claims covering vectors, editing constructs, and manufacturing methods
  • product-specific claims covering final constructs and dose administration
• Exclusivity is often longer in practice due to manufacturing constraints and reimbursement ramp-up, even after legal barriers decline.

How should investors and R&D teams read patent signals in oncology?

Patent signal indicators with business impact

• Claim scope durability: broad early claims plus later narrowed clinical/regimen claims usually yields stronger long-term enforceability.
• Number of independent claim groups: a higher count across modalities and methods reduces the probability that one invalidation wipes exclusivity.
• Continuations and divisional strategy: late-stage filings can preserve claim breadth while meeting regulatory timelines.
• Combination claim coverage: protects revenue where the standard of care uses multi-agent regimens.

Translating patent activity into commercial outcomes

• If patent portfolios show dense “combination + biomarker + regimen” coverage, the brand typically maintains higher price integrity longer.
• If portfolios rely heavily on a single composition claim without robust follow-on, value erosion usually accelerates near expiry.

What is the practical patent risk map for the Antineoplastic Agents class?

Common risk zones across the MeSH class

• Foundational composition claims expire and follow-on protection is narrow or easily designed around.
• Prosecution histories limit enforcement positions later.
• Regimen-specific claims may not protect broad off-label use, reducing practical market coverage.
• Market shifts to new combinations can reduce reliance on expiring indication claims.

Value-protecting zones

• Biomarker-defined patient subsets that remain clinically relevant across changing guidelines.
• Manufacturing and formulation improvements that biosimilar and generic products cannot copy without risk.
• Partner drug exclusivity: even when one drug faces generic risk, combination value can persist if the partner remains protected.

What should be built into a patent landscape framework for this class?

Required layers for a decision-grade oncology landscape

1. Modality filter (small molecule, antibody, other biologic, cell/gene).
2. MOA and target segmentation (kinase family, checkpoint pathway, DNA damage repair, etc.).
3. Indication segmentation (solid tumors vs hematologic; line-of-therapy; biomarker subsets).
4. Regimen and combination segmentation (pairing with standard-of-care partners).
5. Jurisdictional enforcement view (U.S. Orange Book vs E.U. SPC vs national frameworks).

Deliverables that directly affect investment and R&D decisions

• Expiry schedule by jurisdiction and claim category.
• Patent family completeness check across:
  • composition
  • formulation
  • method of treatment
  • combination regimens
  • manufacturing process
• Freedom-to-operate prioritization by:
  • earliest-at-risk date
  • likely design-around routes
  • litigation history markers in the same MOA family

Key Takeaways

• Antineoplastic demand is driven by regimen expansion, biomarker-defined patient selection, and the economics of net pricing under payer pressure.
• Oncology patent landscapes typically rely on stacked exclusivity across composition, method-of-treatment, formulation, manufacturing, and combination regimens.
• MeSH “Antineoplastic Agents” is a taxonomy that spans multiple modalities and does not map cleanly to legal exclusivity; analytics must segment by modality, MOA, and indication.
• Patent value erosion usually accelerates when portfolios lack robust follow-on combinations and when enforceable claim scope narrows during prosecution.
• Decision-grade landscapes should include jurisdictional expiry mapping, claim-category breakdowns, and combination/regimen coverage to forecast revenue protection and at-risk windows.

FAQs

1. How is a MeSH category different from a patent landscape definition?
   MeSH is a subject classification for drug concepts used in indexing and searching; patent landscapes are defined by legal claims, jurisdictions, and priority and expiry schedules.

2. Which claim categories most often extend exclusivity in oncology?
   Method-of-treatment (indication and biomarker subsets), combination regimens, formulations (including solid-state and delivery), and manufacturing/process improvements.

3. What market dynamic most directly compresses prices in antineoplastic drugs?
   Increased competitive entry and payer-driven net price pressure, especially as biosimilars or generics enter within similar MOA families and as labels expand.

4. Why do combination claims matter even when the core composition patent expires?
   Standard-of-care regimens often rely on multi-agent therapy; combination protection can preserve market differentiation and reduce design-around opportunities.

5. What is the fastest way to misread oncology patent risk at the MeSH class level?
   Treating the entire “Antineoplastic Agents” set as one homogeneous portfolio without modality, MOA, biomarker dependency, and jurisdictional claim segmentation.

---

References

[1] National Library of Medicine. “MeSH Browser: Antineoplastic Agents.” U.S. National Library of Medicine, Bethesda, MD. https://meshb.nlm.nih.gov/
[2] U.S. Food and Drug Administration. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” https://www.accessdata.fda.gov/scripts/cder/ob/
[3] European Medicines Agency. “Supplementary Protection Certificates (SPCs).” https://www.ema.europa.eu/